Loading…
Vivos Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in VVOS.
▼ -99.8% over 5Y.
today you would have $1.39▼ -99.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $2.03 | $4.29 | $12.44 | $10.05 | $56.25 | $147.75 | |
| P/S | 2.1x | 1.6x | 1.7x | 2.5x | 0.7x | 3.1x | 8.2x |
| P/B | 3.2x | — | 3.2x | 82.7x | 2.5x | 2.0x | 6.4x |
| EPS | -$2.07 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SBFMSunshine Biopharma Inc. | $1.15 | — | 0.0x | — | -21.92% | $4.46M |
| SILOSilo Pharma, Inc. | $2.54 | — | 0.5x | — | -91.23% | $4.45M |
| XAIRBeyond Air, Inc. | $4.48 | 0.0x | 0.4x | — | -519.51% | $4.41M |
| ELABPMGC Holdings Inc. | $5.31 |
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Company description provided by Yahoo Finance.
| -$2.22 |
| -$11.14 |
| -$25.90 |
| -$24.00 |
| -$35.00 |
| Profit margin | -109.29% | -121.37% | -74.09% | -98.42% | -148.81% | -120.15% | -92.28% |
| ROE | -140.01% | — | -140.01% | -3304.87% | -496.67% | -79.44% | -71.27% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.2x |
| — |
| -105.22% |
| $4.3M |
| APVOAptevo Therapeutics Inc. | $2.37 | 0.0x | 0.6x | — | -420.34% | $4.26M |
| XRTXXORTX Therapeutics Inc. | $2.34 | — | 1.6x | — | -99.24% | $4.25M |